EP4021387A1 - Compositions de soins personnels pour traiter des bactéries provoquant des odeurs et leurs procédés d'utilisation - Google Patents

Compositions de soins personnels pour traiter des bactéries provoquant des odeurs et leurs procédés d'utilisation

Info

Publication number
EP4021387A1
EP4021387A1 EP19817074.8A EP19817074A EP4021387A1 EP 4021387 A1 EP4021387 A1 EP 4021387A1 EP 19817074 A EP19817074 A EP 19817074A EP 4021387 A1 EP4021387 A1 EP 4021387A1
Authority
EP
European Patent Office
Prior art keywords
composition
skin
weight
bacteria
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19817074.8A
Other languages
German (de)
English (en)
Inventor
Aixing Fan
Min Li
Thomas Boyd
Shyamala Pillai
Katie Truong
Laurence Du-Thumm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Colgate Palmolive Co
Original Assignee
Colgate Palmolive Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Colgate Palmolive Co filed Critical Colgate Palmolive Co
Publication of EP4021387A1 publication Critical patent/EP4021387A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations

Definitions

  • compositions such as antiperspirant/deodorant compositions
  • bacteria There is a wide array of bacteria that reside on our skin, especially in the axillary region.
  • the most common bacterial genus on our skin is Staphylococcus bacteria, which includes Staphylococcus epidermidis, one of the most studied and known microbes.
  • Staphylococcus epidermidis is a beneficial bacteria. Specifically, it produces antimicrobial peptides (AMP) and provides a barrier against the colonization of potentially pathogenic microbes and the overgrowth of opportunistic pathogens.
  • AMP antimicrobial peptides
  • Corynebacteria are the primary source of undesired, pungent underarm odors.
  • compositions such as antiperspirant/deodorant compositions, that selectively inhibit, treat, or reduce the growth of detrimental bacteria, such as Corynebacteria , and/or promote the growth of beneficial bacteria, such as Staphylococcus epidermidis.
  • compositions including a base and one or more fatty alcohols.
  • the one or more fatty alcohols may be present in an amount effective to selectively inhibit the growth of at least one detrimental Gram-positive bacteria and promote the growth of at least one beneficial Gram-positive bacteria on skin.
  • the one or more fatty alcohols may include one or more of 2-prop yl-heptanol, 2-butyl octanol, 2-pentyl- 1-nonanol, 2-hexyl- 1-decanol, 2-heptyl-l-undecanol, 2-octyl- 1-dodecanol, 2-nonyl-l-tridecanol, 2-decyl-tetradecanol, 2-undecyl-l-pentadecanol, 2- dodecyl-hexadecanol, 2-tridecyl-heptadecanol, 2-tetradecyl-l-octadecanol, 2-pentadecyl-l- nonadecanol, 2-hexadecyl-l-eicosanol, 2-heptadecyl-l-heneicosanol, 2-octade
  • the one or more fatty alcohols may be present in an amount of from about 0.01 weight % to about 25 weight %, preferably about 0.01 weight % to about 5 weight %, more preferably in an amount of at least 0.16 weight% to about 5 weight %, or about 1.6 weight % to about 5 weight %, based on a total weight of the composition.
  • the one or more fatty alcohols are present in an amount effective to selectively inhibit the growth of detrimental bacteria, such as Corynebacterium.
  • one or more fatty alcohols are present in an amount effective to selectively inhibit the growth of Cornebacterium striatum.
  • the one or more fatty alcohols are present in an amount effective to selectively promote the growth of beneficial bacteria, such as Staphylococcus.
  • beneficial bacteria such as Staphylococcus.
  • the one or more fatty alcohols are present in an amount effective to selectively promote the growth of S. epidermidis, S. haemolyticus, or combinations thereof.
  • the composition may be a personal care composition.
  • the personal care composition may be or include a cleanser, a lotion, a cream, an emulsion, a shampoo, a conditioner, a shower gel, an antiperspirant, a deodorant, a depilatory, a lipstick, a foundation, a mascara, a sunless tanner, or a sunscreen lotion.
  • the composition may include a deodorant active or an antiperspirant active.
  • the foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a method for selectively treating the growth of a detrimental bacteria and promoting the growth of a beneficial bacteria on skin.
  • the method may include contacting any one of the compositions disclosed herein with the skin.
  • the detrimental bacteria may include Corynebacterium.
  • the beneficial bacteria may include Staphylococcus.
  • the composition may be contacted with the skin daily for at least one week, at least two weeks, at least three weeks, or at least four weeks.
  • the foregoing and/or other aspects and utilities embodied in the present disclosure may be achieved by providing a method for producing or enhancing the production of antimicrobial peptides on skin.
  • the method may include contacting any one of the compositions disclosed herein with the skin.
  • the method may further include promoting the growth of Staphylococcus on the skin to thereby produce or enhance the production of the antimicrobial peptides on the skin.
  • the composition may be contacted with the skin daily for at least one week, at least two weeks, at least three weeks, or at least four weeks.
  • compositions for use in treating or inhibiting the growth of a detrimental bacteria on skin may include a base and one or more fatty alcohols, wherein the one or more fatty alcohols are present in an amount effective to treat or inhibit the growth of the detrimental bacteria.
  • the detrimental bacteria may include Corynebacterium.
  • compositions for use in promoting the growth of a beneficial bacteria on skin may include a base and one or more fatty alcohols, wherein the one or more fatty alcohols are present in an amount effective to promote the growth of the beneficial bacteria.
  • the beneficial bacteria may include Staphylococcus.
  • compositions including a base and one or more fatty alcohols for use in selectively inhibiting the growth of at least one detrimental Gram-positive bacteria and promoting the growth of at least one beneficial Gram-positive bacteria on skin.
  • the at least one detrimental Gram-positive bacteria may include Corynebacterium, optionally, Cornebacterium striatum.
  • the at least one beneficial Gram-positive bacteria may include Staphylococcus, optionally, the Staphylococcus comprises S. epidermidis, S. haemolyticus, or combinations thereof.
  • ranges are used as shorthand for describing each and every value that is within the range. It should be appreciated and understood that the description in a range format is merely for convenience and brevity, and should not be construed as an inflexible limitation on the scope of any embodiments or implementations disclosed herein. Accordingly, the disclosed range should be construed to have specifically disclosed all the possible subranges as well as individual numerical values within that range. As such, any value within the range may be selected as the terminus of the range.
  • the term “about,” as used herein, in conjunction with a numeral refers to a value that may be ⁇ 0.01% (inclusive), ⁇ 0.1% (inclusive), ⁇ 0.5% (inclusive), ⁇ 1% (inclusive) of that numeral, ⁇ 2% (inclusive) of that numeral, ⁇ 3% (inclusive) of that numeral, ⁇ 5% (inclusive) of that numeral, ⁇ 10% (inclusive) of that numeral, or ⁇ 15% (inclusive) of that numeral. It should further be appreciated that when a numerical range is disclosed herein, any numerical value falling within the range is also specifically disclosed.
  • free or “substantially free” of a material may refer to a composition, component, or phase where the material is present in an amount of less than 10.0 weight %, less than 5.0 weight %, less than 3.0 weight %, less than 1.0 weight %, less than 0.1 weight %, less than 0.05 weight %, less than 0.01 weight %, less than 0.005 weight %, or less than 0.0001 weight % based on a total weight of the composition, component, or phase.
  • the present inventors have surprisingly and unexpectedly discovered that personal care compositions including one or more fatty alcohols, such as 2-butyl octanol, did not inhibit the growth of and/or promoted the growth of beneficial Gram-positive bacteria, such as Staphylococcus bacteria.
  • the present inventors have also surprisingly and unexpectedly discovered that personal care compositions including one or more fatty alcohols, such as 2-butyl octanol, inhibit, treat, and/or reduce the growth of detrimental bacteria, such as Corynebacterium, especially when present in an amount of at least about 0.16 weight % or greater.
  • compositions such as deodorant or antiperspirant compositions, including one or more fatty alcohols, such as 2- butyl octanol, significantly and selectively reduced the relative abundance of detrimental bacteria (e.g., Corynebacteria ) and increased the relative abundance of beneficial bacteria (e.g., Staphylococcus ) .
  • detrimental bacteria e.g., Corynebacteria
  • beneficial bacteria e.g., Staphylococcus
  • compositions disclosed herein may be or include a personal care composition.
  • personal care composition may refer to a composition for topical application to skin of mammals, especially humans.
  • the personal care composition may generally be a leave-on personal care composition or rinse off personal care composition, and may include any product applied to a human body.
  • the personal care composition is preferably a leave-on personal care composition.
  • the personal care composition may be in any suitable form. Illustrative forms of the personal care composition may be or include, but is not limited to, a liquid, a lotion, a cream, a foam, a scrub, a gel, a soap bar, a toner, applied with an implement or via a face mask, or the like.
  • Illustrative personal care compositions may be or include, but are not limited to, cleansers, lotions, leave-on skin lotions and creams, emulsion, shampoos, conditioners, shower gels, antiperspirants, deodorants, depilatories, lipsticks, foundations, mascara, sunless tanners, sunscreen lotions, or the like.
  • the compositions disclosed herein may be or include an antiperspirant composition, a deodorant composition, or combinations thereof.
  • the compositions may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
  • the composition may be capable of or configured to treat, inhibit, and/or reduce detrimental bacteria on skin.
  • the composition may be capable of treating, inhibiting, and/or reducing odor producing bacteria on skin, thereby reducing odor.
  • the composition may also be capable of or configured to promote the growth of beneficial bacteria on skin.
  • the composition disclosed herein may be capable of or configured to treat, inhibit, and/or reduce the growth of Corynebacterium and/or promote the growth of Staphylococcus bacteria.
  • the composition may further be capable of or configured to enhance or increase a barrier on the skin against colonization of potentially pathogenic microbes.
  • the composition may be capable of or configured to promote antimicrobial peptides (AMP) growth on the skin and provide a barrier against the colonization of potentially pathogenic microbes and the overgrowth of opportunistic pathogens on the skin.
  • AMP antimicrobial peptides
  • the composition may be in the form of an aqueous liquid, a gel, an aerosol, or a cream (e.g., “soft solid”).
  • the composition may be formulated to be a roll-on product.
  • the composition may be an oil in water emulsion or a water in oil emulsion.
  • the forms of these products may be suspensions or emulsions.
  • the composition is an oil in water liquid emulsion.
  • the liquid may be contained in any roll on dispenser that has a ball for applying the composition to the surface of the skin.
  • the composition of the invention may be an oil-in-water liquid roll-on or a water-in-oil gel or a water- in-oil cream.
  • the composition may include one or more fatty alcohols capable of or configured to treat, inhibit, and/or reduce detrimental bacteria.
  • the one or more fatty alcohols may also be capable of or configured to promote the growth of beneficial bacteria on skin.
  • the one or more fatty alcohols may be capable of or configured to treat, inhibit, and/or reduce the growth of Corynebacterium and/or promote the growth of Staphylococcus bacteria.
  • the fatty alcohols may be linear alcohols or branched alcohols.
  • the fatty alcohols may be saturated or unsaturated.
  • Illustrative fatty alcohols may be or include, but are not limited to, C10-C45 branched fatty alcohols, 2-propyl-heptanol, 2-butyl- 1-octanol (2-butyl octanol), 2-pentyl- 1-nonanol, 2-hexyl-l- decanol, 2-heptyl-l-undecanol, 2-octyl- 1-dodecanol, 2-nonyl-l-tridecanol, 2-decyl-tetradecanol, 2-undecyl-l-pentadecanol, 2-dodecyl-hexadecanol, 2-tridecyl-heptadecanol, 2-tetradecyl-l- octadecanol, 2-pentadecyl-l-nonadecanol, 2-hexadecyl-l-eicosanol
  • the one or more fatty alcohols may be present in an amount effective to treat, inhibit, and/or reduce detrimental bacteria on skin.
  • the one or more fatty alcohols may also be present in an amount effective to treat, inhibit, and/or reduce odor producing bacteria on skin.
  • the one or more fatty alcohols may further be present in an amount effective to promote the growth of beneficial bacteria on skin.
  • the one or more fatty alcohols may also be present in an amount effective to enhance or increase a barrier on the skin against colonization of potentially pathogenic microbes.
  • the one or more fatty alcohols may be present in the composition in an amount effective to treat, inhibit, and/or reduce the growth of Corynebacterium and/or promote the growth of Staphylococcus bacteria.
  • an “effective amount,” or similar expressions, of a material or composition may refer to the amount needed to accomplish an intended purpose; for example, to treat, inhibit, and/or reduce detrimental bacteria on skin.
  • the one or more fatty alcohols may be present in an amount of from greater than 0 weight % or about 0.01 weight % to about 25 weight %, based on a total weight of the composition.
  • the one or more fatty alcohols may be present in an amount of from greater than 0 weight %, about 0.01 weight %, about 0.02 weight %, about 0.04 weight %, about 0.08 weight %, about 0.16 weight %, about 0.20 weight %, about 0.25 weight %, about 0.5 weight %, about 0.75 weight %, about 1 weight %, about 1.6 weight %, about 2 weight %, about 5 weight %, about 8 weight %, or about 10 weight % to about 15 weight %, about 18 weight %, about 20 weight %, or about 25 weight %.
  • the one or more fatty alcohols may be present in an amount of from about 0.01 weight % to about 25 weight % or about 0.01 weight % to about 5 weight %, based on a total weight of the composition. In another example, the one or more fatty alcohols may be present in an amount of at least 0.01 weight %, at least 0.02 weight %, at least 0.04 weight %, at least 0.08 weight %, at least 0.16 weight %, at least 0.20 weight %, at least 0.25 weight %, at least 0.5 weight %, at least 0.75 weight %, at least 1 weight %, at least 1.5 weight %, at least 1.6 weight %, at least 1.7 weight %, at least 1.8 weight %, at least 1.9 weight %, at least 2 weight %, at least 3 weight %, at least 4 weight %, at least 5 weight %, at least 8 weight %, at least 10 weight %, at least 15 weight %, at least 18 weight %, at least 20
  • the composition may include an antiperspirant active.
  • Any of the known aluminum containing antiperspirant active materials may be utilized in the composition.
  • Illustrative antiperspirant actives may be or include, but are not limited to, aluminum chlorohydrate, aluminum chloride, aluminum chlorohydrex polyethylene glycol, aluminum chlorohydrex propylene glycol, aluminum dichlorohydrate, aluminum dichlorohydrex polyethylene glycol, aluminum dichlorohydrex propylene glycol, aluminum sesquichlorohydrate, aluminum sesquichlorohydrate polyethylene glycol, aluminum sesquichlorohydrate propylene glycol, aluminum-zirconium octachlorohydrate, aluminum-zirconium octachlorohydrex gly, aluminum-zirconium pentachlorohydrate, aluminum-zirconium pentachlorohydrex gly, aluminum-zirconium tetrachlorohydrate, aluminum-zirconium tetrachlorohydrex gly, aluminum-zirconium t
  • any of the Category I active antiperspirant ingredients listed in the Food and Drug Administration's (FDA) Monograph on Antiperspirant Drug Products for over-the-counter human use (Oct. 10, 1973) may be used (21 CFR 350.10).
  • the antiperspirant active is aluminum chlorohydrate.
  • the antiperspirant active is aluminum zirconium tetrachlorhydrex propylene glycol.
  • the antiperspirant active may be an aluminum salt and/or an aluminum- zirconium salt, such as those described above, that are further stabilized by betaine and a calcium salt. More information betaine and calcium salt stabilized antiperspirant salts may be found in U.S. Patent Application Publication No. 2006/0204463 to Tang et al. In other implementations, the antiperspirant active, such as those described above, is selected to have a low metal to chloride ratio. Examples of these antiperspirant actives may be found in U.S. Pat. No. 6,375,937 to Chopra et al. and in U.S. Patent Application Publication No. 2004/0109833 to Tang et al.
  • an aluminum zirconium tetrasalt or octasalt free of glycine may be used wherein aluminum zirconium salt is stabilized by betaine and has a metal to chloride ratio of about 0.9:1 to about 1.3:1 (and in other embodiments of about 0.9:1 to about 1.2:1 or about 0.9:1 to about 1.1:1).
  • the Al/Zr atomic ratio may be about 3.2:1 to about 4.1:1.0 and the betaine: zirconium mole ratio may be about 0.2:1 to about 3.0:1 (or in other embodiments of about 0.4:l to about 1.5:1).
  • Another salt that may be used is an aluminum chloride salt buffered by betaine, wherein the salt has a metal to chloride ratio of about 0.9: 1 to about 1.3:1 (and in other embodiments of about 0.9: 1 to about 1.2: 1 or about 0.9: 1 to about 1.1:1).
  • the Al/Zr atomic ratio is about 6.2:1 to about 10.0:1 and the betaine:Zr mole ratio is about 0.2:1 to about 3.0:1 (or in other embodiments of about 0.4:1 to about 1.5:1).
  • the betaine in the case of a salt that contains zirconium, is incorporated during the synthesis of the salt so as to maximize the stabilizing effect this ingredient has (especially on the zirconium species).
  • it may be post added to a glycine-free salt along with additional active phase ingredients to form a betaine stabilized active.
  • the antiperspirant active may be a calcium salt stabilized antiperspirant active. Examples of calcium salt stabilized antiperspirant actives may be found in U.S. Patent Application Publication No. 2006/0204463.
  • Examples of commercially available glycine-free low M:C1 ratio tetrasalts and octasalts may be or include, but are not limited to, REZALTM AZP 955 CPG and REZALTM AZP 885 respectively, which are both commercially available from SummitReheis Antiperspirant Actives of Huguenot, NY.
  • REZALTM AZP 955 CPG and REZALTM AZP 885 are both commercially available from SummitReheis Antiperspirant Actives of Huguenot, NY.
  • a more detailed description of making such commercially available salts may be found for example, in U.S. Pat. Nos. 7,074,394 and 6,960,338. Further examples of making these types of salt complexes are described in U.S. Patent Application Publication No. 2004/0198998 and U.S. Pat. No. 7,105,691.
  • Antiperspirant actives may be incorporated into the compositions in an effective amount to reduce the flow or generation of perspiration when applied to skin.
  • the composition may include any one or more of the antiperspirant actives in an amount of from about 1 weight % to about 30 weight %, on an actives basis, based on a total weight of the composition.
  • the composition may include one or more deodorant actives.
  • deodorant actives may be or include, but are not limited to, antimicrobial actives, alcohols, 2,4,4 '-trichloro-2'- hydroxy diphenyl ether (Triclosan), benzethonium chloride, polyhexamethylene biguanides, triethylcitrate, 2-amino-2-methyl-l -propanol (AMP), cetyl-trimethylammomium bromide, cetyl pyridinium chloride, farnesol (3,7,ll-trimethyl-2,6,10-dodecatrien-l-ol), N-(4-chlorophenyl)-N'- (3,4-dichlorophenyl)urea (Triclocarban), silver halides, octoxyglycerin (SensivaTM SC 50) and various zinc salts (for example, zinc ricinoleate), bactericides, bac
  • the term “base” may refer to or encompass all other materials in the composition that are not the antiperspirant active and/or the fatty alcohols.
  • the base may provide or be capable of or configured to provide the form of the composition.
  • the composition may be in the form of an aqueous liquid, a gel, an aerosol, or a cream.
  • the composition is a solid stick or soft solid at ambient room temperature (e.g., about 25 °C).
  • the stick form is an example of a solid form, and the soft solid is a thickened form that may or may not be solid.
  • the stick form may be distinguished from a soft solid in that, in a stick, the formulated product may retain its shape for extended time periods outside the package, the product not losing its shape significantly (allowing for some shrinkage due to solvent evaporation). Adjustment of amounts of gelling or thickening agents may be used in order to form a soft solid or stick.
  • the compression force of a stick product may be greater than 3000 g.
  • the compression force of a stick product may be greater than 3000 g, greater than 4000 g, greater than 4500 g, greater than 5000 g, greater than 6000 g, greater than 7000 g, greater than 8000 g, or greater than 9000 g.
  • the compression force may be from about 3500 g to about 10,000 g.
  • the composition may include one more gelling agents.
  • Gelling agents may be or include, but are not limited to, waxes, esters of fatty acid and fatty alcohol, triglycerides, partially or fully hydrogenated soybean oil, partially or fully hydrogenated castor oil, other partial or fully hydrogenated plant oils, stearyl alcohol, other cosmetically acceptable materials, which are solid or semi solid at room temperature and provide a consistency suitable for application to the skin, or the like, or any combination thereof.
  • the gelling agent may include a combination of hydrogenated soybean oil and a hydrocarbon of the formula C n Fh n+ 2, wherein n is 20 to 100, and the hydrocarbon is at least 90% linear.
  • the fully or partially hydrogenated soybean oil may be or include those described in U.S. Patent Application Publication Nos. 2008/0187504A1 and 2008/0187503A1.
  • the hydrogenated soybean oil from U.S. Patent Application Publication No. 2008/0187504A1 is almost, but not fully hydrogenated.
  • the amount of hydrogenation is measured by the iodine value.
  • the iodine value may be measured by ASTM D5554-95 (2006).
  • the iodine value of the hydrogenated soybean oil used herein is greater than 0 to 20.
  • the iodine value may be 1 to 5.
  • the partially hydrogenated soybean oil from U.S. Patent Application Publication No. 2008/0187503A1 may have a melting point that of about -15°C (5°F) to 38°C (100°F).
  • the melting point may alternatively be 26°C (80°F) to 38°C (100°F).
  • the oil may be partially hydrogenated or a blend of non-hydrogenated with partially or fully hydrogenated oils and/or waxes.
  • the partially or fully hydrogenated soybean oil may be present in an amount of from greater than 0 weight % to about 20 weight %, based on a total weight of the composition. In another example, the partially or fully hydrogenated soybean oil may be present in an amount of from greater than 0 to about 10 weight %, based on a total weight of the composition. In yet another example, the partially or fully hydrogenated soybean oil may be in an amount of at least 1 weight %, 2 weight %, 3 weight %, 4 weight %, 5 weight %, 6 weight %, 7 weight %, 8 weight %, or 9 weight %, based on the total weight of the composition.
  • the amount may be present in an amount of less than 10 weight %, 9 weight %, 8 weight %, 7 weight %, 6 weight %, 5 weight %, 4 weight %, 3 weight %, 2 weight %, 1 weight %, based on a total weight of the composition.
  • the hydrocarbon may be a hydrocarbon of the formula C n Fh n+ 2, where n is 20-100, and where the hydrocarbon may be at least 90% linear.
  • the hydrocarbon may be or include a paraffin.
  • the hydrocarbon may be or include polyethylene/polymethylene.
  • the polyethylene may have a weight average molecular weight of from about 300 kDa to 3000 kDa.
  • the polyethylene may have a melting point of from about 50°C to about 129°C.
  • the composition may include one or more volatile silicones.
  • the volatile silicone may be a volatile cyclic polydimethylsiloxane (cyclomethicone), e.g., cyclopentasiloxane.
  • cyclomethicone volatile cyclic polydimethylsiloxane
  • the term volatile material or volatile silicone may refer to a material or silicone, respectively, that has a measurable vapor pressure at ambient temperature.
  • the volatile cyclic polydimethylsiloxane is cyclomethicone.
  • Various types of cyclomethicones may be used.
  • the volatile silicones are one or more members selected from cyclic polydimethylsiloxanes such as those represented by Formula (I): Formula (I) where n may be an integer with a value of from 3 to 7, particularly from 5 to 6.
  • Illustrative cyclomethicones may be or include, but are not limited to, DC-345 and DC-245, manufactured by Dow Coming Corporation of Midland, MI. These types of cyclomethicones may include a tetramer (octylmethylcyclotetrasiloxane) and/or a pentamer (decamethylcyclopentasiloxane).
  • the amount of any one or more of the volatile silicones present in the composition may be from about 5 weight % to about 70 weight %, based on a total weight of the composition.
  • the volatile silicones may be present in an amount of from about 25 weight % to about 45 weight %, based on a total weight of the composition.
  • the composition may include one or more ionizable inorganic salts.
  • the salts are chosen from NaCl and ZnCh.
  • a salt directly to a portion of the mixture during manufacturing, it is desired to add the salt as a mixture or solution of the salt in a carrier or solvent, particularly water.
  • the composition may include one or more particulates.
  • Illustrative particulates may be or include, but are not limited to, talc, mica, fragrance encapsulates, or hydrophobically modified starches, such as aluminum starch octenyl succinate (MACKADERMTM ASTRO-DRYTM commercially available from McIntyre Group Ltd. of University Park, IL).
  • talc talc
  • mica talc
  • fragrance encapsulates such as aluminum starch octenyl succinate (MACKADERMTM ASTRO-DRYTM commercially available from McIntyre Group Ltd. of University Park, IL).
  • hydrophobically modified starches such as aluminum starch octenyl succinate (MACKADERMTM ASTRO-DRYTM commercially available from McIntyre Group Ltd. of University Park, IL).
  • the composition may include one or more optional ingredients, such as a malodor counteracting alpha, beta-unsaturated ester or mixtures of such materials.
  • the level of the malodor counteracting composition to deliver a perceivable odor control benefit when delivered from an antiperspirant and/or deodorant composition may be from about 0.05 weight % to about 0.45 weight %, based on a total weight of the composition.
  • the alpha, beta-unsaturated ester malodor counteracting materials may be incorporated within the oil phase of the composition. Example of these malodor counteracting components may be found in U.S. Pat. No. 6,610,648 and U.S. Pat. No.
  • Illustrative alpha, beta unsaturated esters may be or include, but are not limited to: (1) 3- phenyl-2-propenoic acid alkyl esters wherein R 1 is a substituent on the benzene ring and is chosen from an alkyl, an alkoxy, an aryl, or a substituted aryl.
  • R 1 is chosen from H, a Ci to Cs alkyl, a Ci to Cs alkoxy, or an aryl; and R 2 is a subsistent group replacing the carboxylic acid hydrogen to form the ester where R 2 has greater than 6 carbon atoms, an aryl, or a substituted aryl group, in certain embodiments R 2 is a Cr, to C12 alkyl or is a benzyl group; and (2) an ester of fumaric or maleic acid having linear ester carbon chains from 3-9 carbons, for example dihexyl fumarate; (3) e-phenyl propenoic acid ester chosen from octyl methoxy cinnamate, phenylethyl cinnamate, benzyl cinnamate; (4) an aliphatic unsaturated ester, such as dihexyl fumarate.
  • the composition may optionally include one or more absorbent materials.
  • absorbent materials may be or include, but are not limited to, corn starch, talc, clay, sodium polyacrylate, cotton fiber, fragrances, or the like, or combinations thereof.
  • the water may make up the balance of the composition.
  • the composition may include water in an amount of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 85%, based on a total weight of the composition.
  • the “total solids of the composition” may refer to the amount of non-volatile materials in the composition. The percent solids is measured by a CEM Smart System moisture/solids analyzer which uses microwave energy to dry the samples. In one implementation, the total solids of the composition may be less than 30%, less than 25%, less than 20%, or less than 15%.
  • any known and/or suitable aerosol propellant may be used.
  • the composition may include one or more antioxidants.
  • antioxidants may be or include, but are not limited to, butylated hydroxytoluene (BHT), pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate (Tinogard TTTM from Ciba/BASF), caffeine, and abies picea extract (GranLuxTM AOX-G4 from Granula, which is a spruce knot extract in butylenes glycol).
  • the composition may include one or more emollients.
  • the emollients may be present in an amount effective to achieve a desired emollient effect. It should be appreciated that emollients are known in the art and are used to impart a soothing effect on the skin.
  • Non-volatile emollients are preferable in the present invention.
  • Classes of non-volatile emollients include non-silicone and silicone emollients.
  • Non-volatile, non-silicone emollients include C 12-15 alkyl benzoate.
  • the non-volatile silicone material may be a polyethersiloxane, polyalkyarylsiloxane or polyethersiloxane copolymer.
  • An illustrative non-volatile silicone material may be or include, but is not limited to, phenyl trimethicone.
  • Non-limiting examples of emollients may be found in U.S. Pat. No. 6,007,799.
  • Illustrative emollients may be or include, but is not limited to, PPG- 14 butyl ether, PPG-3 myristyl ether, stearyl alcohol, stearic acid, glyceryl monoricinoleate, isobutyl palmitate, glyceryl monostearate, isocetyl stearate, sulphated tallow, oleyl alcohol, propylene glycol, isopropyl laurate, mink oil, sorbitan stearate, cetyl alcohol, hydrogenated castor oil, stearyl stearate, hydrogenated soy glycerides, isopropyl isostearate, hexyl laurate, dimethyl brassylate, decyl oleate, diisopropyl adipate, n-dibutyl sebacate, diisopropyl sebacate, 2-ethyl hexyl palmitate, isononyl isononan
  • the one or more emollients may be or include, but are not limited to, linear silicones, cyclic silicones, hydrocarbons, polyhydroxy alcohols having more than 3 carbon atoms, liquid or solid polyalkyleneglycol ethers containing a polypropylene glycol (PPG) moiety and terminating in an alkyl ether, or the like, or combinations thereof.
  • the emollient may be a volatile silicone, as discussed above, having a flash point of 100° C. or less, such as cyclomethicone, cyclopentasiloxane, or trisiloxane.
  • the compositions may include one or more surfactants.
  • the one or more surfactants may be present in an amount of from greater than 0 weight % to about 20 weight %, based on a total weight of the composition.
  • the one or more surfactants may be or include, but are not limited to anionic surfactants, cationic surfactants, amphoteric or zwitterionic surfactants, nonionic surfactants, silicone surfactants, or combinations thereof.
  • Illustrative nonionic surfactants may be or include, but are not limited to, (a) sorbitan esters and ethoxylated sorbitan esters (for example PEG-20 sorbitan isostearate, sorbitan monolaurate, polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-80); (b) ethoxylates (for example, Ceteth-20, PEG-30 castor oil. PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil. Laureth-7, Isolaureth-6, Steareth-10. Steareth-20. Steareth-21, Steareth-100.
  • sorbitan esters and ethoxylated sorbitan esters for example PEG-20 sorbitan isostearate, sorbitan monolaurate, polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-80
  • ethoxylates for example, Ceteth-20, PEG-30 castor oil.
  • PEG esters for example, PEG-8 oleate, PEG-8 laurate, PEG-8 dilaurate.
  • propoxylates for example, PPG-10 butanedio
  • PPG-5-ceteth-20 (f) ethoxylated modified triglycerides (for example, PEG-20 com glycerides. PEG- 12 palm kernel glycerides); (g) alkylphenol aromatic ethoxylates (for example, dinonylphenol ethoxylate with 9 moles of EO, octylphenol ethoxylate with 20 moles of EO, octylphenol ethoxylate with 40 moles of EO): (h) block copolymers that are alkoxylated glycols having ethoxylated and propoxylated segments (for example, POLOXAMERTM 182 and 234.
  • alkylphenol aromatic ethoxylates for example, dinonylphenol ethoxylate with 9 moles of EO, octylphenol ethoxylate with 20 moles of EO, octylphenol ethoxylate with 40 moles of EO
  • the nonionic surfactant includes ethoxylated nonionic surfactants and propoxylated non-ionic surfactants.
  • Example of these include, but are not limited to, Steareth 2, Steareth 20, and Steareth 21.
  • a combination of two surfactants one having an HLB value of 2 to 8 (such as Steareth 2) and the other having an HLB of 9 to 18 (such as Steareth 20 and 21), may be used.
  • the nonionic surfactant is selected such that it has an HLB (hydrophilic- lipophilic balance) value of from about 8 to about 16 or from about 8 to about 12.
  • silicone surfactants may be found in U.S. Pat. No. 6,485,716, which is incorporated herein by reference only for the listing of the silicone surfactants.
  • Illustrative silicone surfactants may be or include, but are not limited to, silicone polyglucosides (for example, octyl dimethicone ethoxy glucoside) and silicone copolyols having an HLB (hydrophilic lipophilic balance) value of less than 8.
  • HLB hydrophilic lipophilic balance
  • the HLB value may be measured in a variety of ways such as described in conventional references or found listed in tables of data recording such values. It is intended that any type of HLB measurement technique may be used.
  • the silicone copolyols may include, but are not limited to, copolyols of the following Lormula (II) and (III).
  • Lormula (II) materials may be represented by: (R 10 ) 3 SiO[(R 11 )2SiO]xSi(R 12 )(R b O((C 2 H 4 O))p(C 3 H 6 O) s (R c )O] y Si(R 13 ) wherein each of R 10 , R 11 , R 12 , and R 13 may be the same or different and each is chosen from C1-C6 alkyl;
  • R b is the radical — C m H2 m — ;
  • R c is a terminating radical which may be hydrogen, an alkyl group of one to six carbon atoms, an ester group such as acyl, or an aryl group such as phenyl;
  • m has a value of two to eight: p and s have values such that
  • each of R 10 , R 11 , R 12 , and R 13 is a methyl group; R c is H; m is preferably three or four whereby the group R b is most preferably the radical — (C3 ⁇ 4)3 — ; and the values of p and s are such as to provide a molecular weight of the oxyalkylene segment — (C 2 H 4 0) P — (C 3 H 6 0) S — of between 1,000 to 3.000. In one embodiment, p and s should each have a value of 18 to 28.
  • the silicone copolyol is dimethicone copolyol.
  • a second siloxane polyether (copolyol) may have the Lormula (III): (R 10 )3SiO[(R u )2SiO]xSi(R 12 )(R b O(C2H4O) p R c )O]ySi(R 13 )3 wherein p has a value of 6 to 16; x has a value of 6 to 100; and y has a value of 1 to 20 and the other moieties have the same definition as defined in Lormula (II).
  • siloxane- oxyalkylene copolymers may, in alternate embodiments, take the form of end-blocked polyethers in which the linking group R b , the oxyalkylene segments, and the terminating radical R occupy positions bonded to the ends of the siloxane chain, rather than being bonded to a silicon atom in the siloxane chain.
  • one or more of the R 10 , R 11 , R 12 , and R 13 substituents that are attached to the two terminal silicon atoms at the end of the siloxane chain may be substituted with the segment — R b — O— (C 2 H 4 0)p— (C3H 6 0) S — R C or with the segment — R b — O— (C 2 H 4 0)— R c .
  • dimethicone copolyols are available either commercially or experimentally from a variety of suppliers including Dow Coming Corporation, Midland, MI; General Electric Company, Waterford, NY; Witco Corp., Greenwich, CT; and Goldschmidt Chemical Corporation, Hopewell, VA.
  • Examples of products include DOW CORNING 5225C from Dow Corning, which is a 10% dimethicone copolyol in cyclomethicone; DOW CORNING 2-5185C, which is a 45-49% dimethicone copolyol in cyclomethicone; SILWET L-7622 from Witco; ABIL3 EM97 from Goldschmidt, which is an 85% dimethicone copolyol in D5 cyclomethicone; and various dimethicone copolyols available either commercially or in the literature.
  • the dimethicone copolyols in cyclomethicone may be used. While a concentration of 10 weight % in cyclomethicone may often be seen commercially, other concentrations may be made by stripping off the cyclomethicone or adding additional cyclomethicone.
  • the higher concentration materials such as DOW CORNING 2-5185 may be used in at least one implementation.
  • the silicone copolyol may be present in an amount of from about 0.5 weight % to about 5 weight %, or about 1 weight % to about 2 weight %, based on a total weight of the composition.
  • Illustrative anionic surfactants may also be or include, but are not limited to, sodium lauryl sulfate, sodium cocoyl monoglyceride sulfonate, sodium lauryl sarcosinate, sodium lauryl isoethionate, sodium laureth carboxylate, and sodium dodecyl benzenesulfonate.
  • Examples of zwitterionic surfactants include those which may be broadly described as derivatives of aliphatic quaternary ammonium, phosphonium, and sulfonium compounds, in which the aliphatic radicals may be straight chain or branched and wherein one of the aliphatic substituents contains from about 8 to 18 carbon atoms and one contains an anionic water- solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • Illustrative zwitterionic surfactants may be or include, but are not limited to 4-[N,N-di(2-hydroxyethyl)-N- octadecylammonio] -butane- 1 -carboxylate; 5 - [S -3 -hydroxypropyl-S -hexadecylsulfonio] -3 - hydroxypentane-l-sulfate; 3-[P,P-P-diethyl-P-3,6,9trioxatetradecyl-phosphonio]-2- hydroxypropane- 1 -phosphate; 3-[N,N-dipropyl-N-3dodecoxy-2-hydroxypropylammonio]- propane- 1 -phosphonate; 3 -(N,N-di-methy-N -hexadecylammonio)propane- 1 - sulfonate; 3 -(N,N- di
  • amphoteric surfactants include those which may be broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical may be straight chain or branched and wherein one of the aliphatic substituents contains from 8 to 18 carbon atoms and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate. Examples of compounds falling within this definition are sodium 3- dodecylaminopropionate and sodium 3-dodecylaminopropane sulfonate. Further amphoteric surfactants are described in U.S. Pat. No. 2,658,072, U.S. Pat. No. 2,438,091 and U.S. Pat. No. 2,528,378.
  • the preferred amphoteric surfactants are betaines.
  • Illustrative betaines useful herein may be or include, but are not limited to, the high alkyl betaines such as coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxy-methyl betaine, lauryl dimethyl alpha-carboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, lauryl bis-(2-hydroxyethyl) carboxy methyl betaine, stearyl bis- (2-hydroxypropyl)carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, lauryl bis-(2-hydroxypropyl) alpha-carboxyethyl betaine, or the like, or combinations thereof.
  • the sulfobetaines may be represented by coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, amido betaines, amidosulfobetaines, or the like
  • compositions as disclosed herein are described and claimed with reference to their ingredients, as is usual in the art.
  • ingredients may in some instances react with one another such that the true composition of the final formulation may not correspond exactly to the ingredients listed.
  • the disclosure may extend to the product of the combination of the listed ingredients.
  • compositions of the present disclosure may be manufactured using methods known in the art. Generally, the ingredients are combined and heated to melt the components (other than inert filler), and the melted components (together with particulate inert filler) are mixed. Desirably, volatile materials, such as the fragrance materials, are incorporated in the composition in the latter stages of the mixing cycle, in order to avoid volatilization thereof. After mixing, the molten composition may be poured directly into the dispensers, after which the compositions harden into a solid, and the container is capped to preserve the product until use.
  • volatile materials such as the fragrance materials
  • compositions disclosed herein may be applied to the skin of mammals.
  • the compositions disclosed herein may be applied to the skin in the axillary area of a human.
  • the present disclosure may provide methods for treating, inhibiting, and/or reducing the growth of undesirable odor-causing bacteria on skin.
  • the present disclosure may provide methods for treating, inhibiting, and/or reducing the growth of Corynebacterium.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal.
  • the method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal.
  • the method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to treat, inhibit, and/or reduce the growth of detrimental bacteria.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more.
  • the method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
  • the present disclosure may also provide methods for reducing odor producing bacteria on skin.
  • the present disclosure may provide methods for treating, inhibiting, and/or reducing the amount of Corynebacterium on skin.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal.
  • the method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal.
  • the method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to treat, inhibit, and/or reduce the amount of detrimental bacteria.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more.
  • the method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
  • the present disclosure may also provide methods for promoting the growth of beneficial bacteria on skin.
  • the present disclosure may provide methods for promoting the growth of Staphylococcus bacteria.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal.
  • the method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal.
  • the method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to promote the growth of beneficial bacteria.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more.
  • the method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
  • the present disclosure may also provide methods for producing or enhancing the production of antimicrobial peptides on the skin.
  • the present disclosure may provide methods for promoting the growth of Staphylococcus bacteria, which produce antimicrobial peptides.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal to promote the growth of Staphylococcus bacteria.
  • the method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal.
  • the method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to promote the growth of beneficial bacteria.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more.
  • the method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
  • the present disclosure may also provide methods for providing, enhancing, or otherwise increasing a barrier on skin against the colonization of potentially pathogenic microbes.
  • the present disclosure may provide methods for promoting the growth of Staphylococcus bacteria, which provides or enhances the barrier against pathogenic microbes.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal to promote the growth of Staphylococcus bacteria.
  • the method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal.
  • the method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to promote the growth of beneficial bacteria.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more.
  • the method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
  • the present disclosure may provide methods for selectively treating, increasing, decreasing, promoting the growth of, and/or inhibiting the growth of one or more Gram-positive bacteria.
  • Gram-positive bacteria may be or include, but are not limited to, bacteria of the genera Listeria, Staphylococcus, Streptococcus, Bacillus, Corynebacterium, Enterococcus, Peptostreptococcus, Clostridium, or the like, or combinations thereof.
  • Illustrative species may be or include, but are not limited to, Listeria monocytogenes, Staphylococcus aureus (including methicillin-resistant S.
  • Staphylococcus epidermidis Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Bacillus cereus, Staphylococcus haemolyticus, Staphylococcus epidermidis, Corynebacterium striatum, Bacillus anthracia, Clostridium botulinum, Clostridium perfringens, Clostridium difficile, Clostridium tetani, Corynebacterium diphtheriae, Corynebacterium ulcerans, Enterococcus faecium (including vancomycin-resistant E.
  • the methods may include selectively treating, increasing, decreasing, promoting the growth of, and/or inhibiting the growth of one or more Gram-positive bacteria on skin in mammals.
  • the method may include selectively increasing or promoting the growth of beneficial bacteria, such as Staphylococcus, while inhibiting or reducing the growth of detrimental bacteria, such as Corynebacterium.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal.
  • the method may also include applying or contacting any one of the compositions disclosed herein to the skin in the axillary area of the mammal.
  • the method may also include administering any one of the compositions disclosed herein to the mammal in an amount effective to selectively treat, decrease, promote the growth of, and/or inhibit the growth of one or more Gram-positive bacteria.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin of the mammal at least once a day, at least two times a day, at least three times a day, or more.
  • the method may include maintaining contact of the compositions disclosed herein to the skin for at least 1 hour, at least 3 hours, at least 5 hours, at least 10 hours, at least 15 hours, or at least 18 hours.
  • the method may include applying or contacting any one of the compositions disclosed herein to the skin daily for at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, or more.
  • the present disclosure may provide a composition for use in treating, inhibiting, and/or reducing the growth of detrimental bacteria on skin.
  • the composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
  • the present disclosure may provide a composition for use in reducing odor producing bacteria on skin.
  • the composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
  • the present disclosure may provide a composition for use in promoting the growth of beneficial bacteria on skin.
  • the composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
  • the present disclosure may provide a composition for use in producing or enhancing the production of antimicrobial peptides on the skin.
  • the composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
  • the present disclosure may provide a composition for use in providing, enhancing, or otherwise increasing a barrier on skin against the colonization of potentially pathogenic microbes.
  • the composition may include a base, an antiperspirant and/or a deodorant active, one or more fatty alcohols (e.g., 2-butyl- 1-octanol), or combinations thereof.
  • the expression or term “treating, inhibiting, and/or reducing bacterial growth” or similar expressions may refer to inhibition of the growth and/or reduction in the number of bacteria on a substrate (e.g., skin). Further, as used herein, the expression or term “promoting the growth of bacteria” or similar expressions may refer to the enhancement or increase in the rate of the growth of the bacteria without intervention, and/or increase in the number of bacteria on a substrate. The increase or decrease in the bacteria may be more than expected without intervention with the methods and/or compositions disclosed herein.
  • compositions and methods disclosed herein may be equally applied to and performed on animal subjects, particularly mammalian subjects (e.g., mice, rats, dogs, cats, rabbits, horses, etc.), avian subjects (e.g., parrots, geese, quail, pheasant, etc.), livestock (e.g., pigs, sheep, goats, cows, chickens, turkey, duck, ostrich, emu, etc.), reptile and amphibian subjects.
  • mammalian subjects e.g., mice, rats, dogs, cats, rabbits, horses, etc.
  • avian subjects e.g., parrots, geese, quail, pheasant, etc.
  • livestock e.g., pigs, sheep, goats, cows, chickens, turkey, duck, ostrich, emu, etc.
  • reptile and amphibian subjects e.g., reptile and amphibian subjects.
  • topically acceptable may refer to any ingredient that is present in a composition as described in an amount and form which does not render the composition unsafe for use on surfaces of skin.
  • the efficacy of 2-butyl octanol for selectively promoting, inhibiting, reducing, and/or treating bacterial growth was evaluated. Particularly, the efficacy of 2-butyl octanol for selectively promoting, inhibiting, reducing, and/or treating bacterial growth of Corynebacterium and Staphylococcus was evaluated.
  • an active solution was prepared by emulsifying 2-butyl octanol with a nonionic surfactant, namely, Polysorbate 80.
  • the active solution included the 2-butyl octanol and the Polysorbate 80 in a ratio of about 83:17. Both positive controls (including no active solution) and negative controls (including no bacteria) were also prepared.
  • a 96-well plate was utilized to evaluate the growth of the respective bacteria at varying dilutions.
  • Each of the wells of a 96-well plate was aseptically filled with about 100 pL of Tryptic Soy Broth (TSB).
  • TTB Tryptic Soy Broth
  • about 100 pL of either the active solution (including the 2-butyl octanol and Polysorbate 80) or the desired solvent for the respective positive and negative controls was added to thereby provide a total of about 200 pL in the first well of the each respective row.
  • a multi-channel pipette was then utilized to prepare a two-fold dilution in each column.
  • a multi-channel pipette set to about 100 pL was utilized to mix and transfer about 100 pL of the 200 pL from the wells of the first column to the respective wells of a subsequent column. This was repeated for each of the remaining eleven columns. About 100 pL of the twelfth column was removed, thereby leaving about 100 pL in each of the 96 wells.
  • For the negative control well about 100 pL of a solvent that does not promote bacterial growth was added.
  • a phosphate buffered saline (PBS) was utilized for the negative control.
  • the 2-butyl octanol selectively or preferably inhibited the bacterial growth of Corynebacterium and promoted the growth of Staphylococcus. Specifically, the presence of 2-butyl octanol, surprisingly and unexpectedly, did not inhibit the growth of and/or promoted the growth of S. epidermidis and S. hominis when present in an amount of about 0.02 weight % to about 5.2 weight %. Conversely, when 2-butyl octanol was present in an amount of at least about 1.6% or greater the growth of C. stratium was completely inhibited (Table 3). It should be appreciated that amounts of 2-butyl octanol greater than about 5.2 weight % were not measured as the system because too turbid to be measured.
  • a control or base deodorant composition (1) and a test deodorant composition including 2-butyl octanol were prepared by combining the ingredients/components according to Table 4.
  • the control (1) and test (2) deodorant compositions were evaluated in an in-house panel study with 11 subjects. Each of the subjects used the control (1) and test (2) deodorant compositions once daily for four weeks. Specifically, each of the subjects used the control deodorant composition (1) in one underarm and the test deodorant composition (2) in the other underarm. After four weeks of daily usage, samples were collected from the underarm and bacteria genomic analysis (16S rRNA sequencing) was performed on these samples. The results of the evaluation are summarized in Table 5.
  • control deodorant composition (1) decreased the relative abundances of both the Corynebacteria and Staphylococcus bacteria.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des compositions, telles que des compositions de soins personnels, et des procédés d'inhibition sélective de la croissance d'une bactérie nuisible et de promotion de la croissance d'une bactérie bénéfique. La composition peut comprendre une base et un ou plusieurs alcools gras. Le ou les alcools gras peuvent être présents en une quantité efficace pour inhiber sélectivement la croissance d'au moins une bactérie Gram-positive nuisible et favoriser la croissance d'au moins une bactérie Gram-positive bénéfique sur la peau. Les bactéries Gram-positives nuisibles peuvent comprendre Corynebacterium, et les bactéries Gram-positives bénéfiques peuvent comprendre Staphylococcus.
EP19817074.8A 2019-11-14 2019-11-14 Compositions de soins personnels pour traiter des bactéries provoquant des odeurs et leurs procédés d'utilisation Pending EP4021387A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/061522 WO2021096518A1 (fr) 2019-11-14 2019-11-14 Compositions de soins personnels pour traiter des bactéries provoquant des odeurs et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
EP4021387A1 true EP4021387A1 (fr) 2022-07-06

Family

ID=68808608

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19817074.8A Pending EP4021387A1 (fr) 2019-11-14 2019-11-14 Compositions de soins personnels pour traiter des bactéries provoquant des odeurs et leurs procédés d'utilisation

Country Status (6)

Country Link
EP (1) EP4021387A1 (fr)
CN (1) CN114650805A (fr)
AU (1) AU2019474692C1 (fr)
BR (1) BR112022008793A2 (fr)
MX (1) MX2022005497A (fr)
WO (1) WO2021096518A1 (fr)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438091A (en) 1943-09-06 1948-03-16 American Cyanamid Co Aspartic acid esters and their preparation
US2528378A (en) 1947-09-20 1950-10-31 John J Mccabe Jr Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same
US2658072A (en) 1951-05-17 1953-11-03 Monsanto Chemicals Process of preparing amine sulfonates and products obtained thereof
ATE200220T1 (de) * 1995-06-23 2001-04-15 Dalli Werke Waesche & Koerperp Mehrkomponentenkonservierungsmittel für haar- und körperreinigungsmittel
ZA966814B (en) 1995-08-18 1998-02-12 Colgate Palmolive Co Clear cosmetic gel composition.
DE19643585A1 (de) * 1996-10-22 1998-04-23 Beiersdorf Ag Antiadhäsive Sphingolipide
WO2000051560A1 (fr) 1999-03-02 2000-09-08 Shaw Mudge & Company Compositions de parfums et de saveurs contenant des agents d'elimination d'odeurs
US6375937B1 (en) 2000-10-20 2002-04-23 Colgate-Palmolive Company Antiperspirant salts for enhanced cosmetic products
US6610648B2 (en) 2000-12-22 2003-08-26 Givaudan Sa Malodor counteractant compositions
US6485716B1 (en) 2001-10-05 2002-11-26 Colgate-Palmolive Company High efficacy liquid gel product
US6960338B2 (en) 2002-06-28 2005-11-01 Reheis, Inc. Amino acid free stable aluminum/zirconium antiperspirant solution
US20040109833A1 (en) 2002-12-09 2004-06-10 Xiaozhong Tang High efficacy, low irritation aluminum salts and related products
US20040198998A1 (en) 2003-04-04 2004-10-07 Marian Holerca Glycine-free antiperspirant salts with betaine for enhanced cosmetic products
US7105691B2 (en) 2003-06-26 2006-09-12 Colgate-Palmolive Company Aluminum / zirconium / glycine antiperspirant actives stabilized with Betaine
US7074394B2 (en) 2003-07-22 2006-07-11 Reheis, Inc. Stable aluminum/zirconium antiperspirant solution free of amino acid and polyhydric alcohol
ATE342105T1 (de) * 2003-08-26 2006-11-15 Johnson & Johnson Consumer Fr Stabilisiertes antitranspirantmittel sojaprodukte enthaltend
AR045608A1 (es) 2003-09-08 2005-11-02 Colgate Palmolive Co Gel transparente antitranspirante con bajo contenido de glicol
DE102004032734A1 (de) * 2004-03-18 2005-10-06 Henkel Kgaa Präbiotisch wirksame Substanzen für Deodorantien
US7704531B2 (en) 2005-02-18 2010-04-27 Colgate-Palmolive Company Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine
US7976828B2 (en) 2007-02-02 2011-07-12 Colgate-Palmolive Company Antiperspirant/deodorant composition
US9789038B2 (en) 2007-02-02 2017-10-17 Colgate-Palmolive Company Antiperspirant/deodorant compositions
EP2353579B1 (fr) * 2010-02-09 2018-12-05 Colgate-Palmolive Europe SARL Composition déodorante
DE102010013274A1 (de) * 2010-03-29 2011-11-17 Beiersdorf Ag Mikrobiologisch stabile anwendungsfreundliche Zubereitungen
EP3848015A1 (fr) * 2016-12-27 2021-07-14 Colgate-Palmolive Company Composition antitranspirante/désodorisante

Also Published As

Publication number Publication date
CN114650805A (zh) 2022-06-21
MX2022005497A (es) 2022-06-02
BR112022008793A2 (pt) 2022-10-04
AU2019474692A1 (en) 2022-05-26
AU2019474692C1 (en) 2024-05-09
WO2021096518A1 (fr) 2021-05-20
AU2019474692B2 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
US7976829B2 (en) Antiperspirant/deodorant compositions
CN1299270A (zh) 包含1,2－己二醇的止汗组合物
US6613312B2 (en) Antiperspirant products made from wet-milled anhydrous antiperspirant salts
AU2019474692C1 (en) Personal care compositions for treating odor causing bacteria and methods for the same
US11331253B2 (en) Personal care compositions for treating odor causing bacteria and methods for the same
US10406085B2 (en) Antiperspirant composition
US20170281517A1 (en) Sweat-inhibiting and/or deodorizing cosmetic agents with low emulsifier content
US20170216156A1 (en) Performance-enhanced antiperspirants
EP3493786B1 (fr) Actif et methode correspondante pour reduire les mauvaises odeurs
EP3171852B1 (fr) Compositions anti-transpirantes contenant du disuccinate d'éthylènediamine
JP2012219122A (ja) 新規なシリコーン誘導体
US20130230475A1 (en) Antiperspirant emulsion products and processes for making the same
EP3027282A1 (fr) Compositions anti-transpirantes/déodorantes
DE102015223837A1 (de) Deodorantien mit Metallpartikeln und Salzen der Kohlensäure
CN118475334A (zh) 止汗剂组合物
JP2013213171A (ja) 新規なシリコーン誘導体
JP2013129721A (ja) 新規なシリコーン誘導体

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)